US medical technology company II has developed a wearable insulin delivery device that provides type Valeritas diabetes patients with a low-dose, continuous supply of insulin, as well as intravenous insulin doses when required. The V-Go system adheres to a flat part of the body and can be filled by the user for both continuous supply and top-up bolus doses. Patients and their healthcare providers liaise to determine the appropriate insulin doses. However, V-Go does not replace the need for blood glucose monitoring. Rather, it provides a discrete baseline insulin dose with the ability to administer additional doses using a single delivery system.
US medical technology company Valeritas has developed a wearable insulin delivery device that provides type II diabetes patients with a low-dose, continuous supply of insulin, as well as intravenous insulin doses when required. The V-Go system adheres to a flat part of the body and can be filled by the user for both continuous supply and top-up bolus doses. Patients and their healthcare providers liaise to determine the appropriate insulin doses. However, V-Go does not replace the need for blood glucose monitoring. Rather, it provides a discrete baseline insulin dose with the ability to administer additional doses using a single delivery system.